This article was originally published by Healio Once-weekly selinexor, bortezomib and dexamethasone improved outcomes compared with twice-weekly...
Myeloma NZ
CAR T-Cell Therapies Show Promise for Multiple Myeloma, but Hurdles Remain
This article was originally published by AJMC There are promising signs that chimeric antigen receptor (CAR) T-cell therapies might lead to...
Dr. Kumar on Stem Cell Mobilization in Multiple Myeloma
This article originally published by OncLive Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses stem cell mobilization multiple...
Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows
First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple...
Multiple myeloma triple therapy now on PBS
This article was originally published by Hostpital and Healthcare. Australians with newly diagnosed multiple myeloma (MM) can now access a treatment...
Subcutaneous vs intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Background | Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and...
GNS Healthcare Launches In Silico Multiple Myeloma “Patient”
GNS Healthcare, a precision medicine company leveraging artificial intelligence to model individual patients’ response to drug treatment, have...
MRP a valuable risk assessment tool for newly diagnosed multiple myeloma
A clinical prediction model for myeloma has been shown to be “a robust and valuable tool” in a real-world population of Danish patients.
Dr. Hari on the Role of MRD in Multiple Myeloma
Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin…
Study Identifies Independent Predictors of Smoldering Multiple Myeloma Progression
A series of molecular abnormalities in smoldering multiple myeloma that are independent predictors of progression to multiple myeloma were...
Article of the week: Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
Myeloma Australia's Medical and Scientific Advisory Group (MSAG) presents the article of the week. Lenalidomide, bortezomib, and dexamethasone (RVd)...
Multiple Myeloma Research Review
Highlights include: Associations with OS in NZ MM patients VTE risk with lenalidomide regimens for MM despite thromboprophylaxis Retrospective study...